CoChat
Sign Up
Cited by 887Antiplatelet Therapy and Cardiovascular DiseasesCoronary Interventions and DiagnosticsAcute Myocardial Infarction Research

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting

Open access
Collet, Jean-Philippe, Cuisset, Thomas, Rangé, Grégoire, Cayla, Guillaume, Elhadad, Simon, Pouillot, Christophe, Henry, Patrick, Motreff, Pascal, Carrié, Didier, Boueri, Ziad, Belle, Loic, Van Belle, Eric, Rousseau, Hélène, Aubry, Pierre, Monségu, Jacques, Sabouret, Pierre, O'Connor, Stephen A., Abtan, Jérémie, Kerneis, Mathieu, Saint-Etienne, Christophe, Barthélémy, Olivier, Beygui, Farzin, Silvain, Johanne, Vicaut, Eric, Montalescot, Gilles·2012·New England Journal of Medicine
DOI 10.1056/nejmoa1209979
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Patients' responses to oral antiplatelet therapy are subject to variation. Bedside monitoring offers the opportunity to improve outcomes after coronary stenting by individualizing therapy. METHODS: We randomly assigned 2440 patients scheduled for coronary stenting at 38 centers to a strategy of platelet-function monitoring, with drug adjustment in patients who had a poor response to antiplatelet therapy, or to a conventional strategy without monitoring and drug adjustment. The primary end point was the composite of death, myocardial infarction, stent thrombosis, stroke, or urgent revascularization 1 year after stent implantation. For patients in the monitoring group, the VerifyNow P2Y12 and aspirin point-of-care assays were used in the catheterization laboratory before stent implantation and in the outpatient clinic 2 to 4 weeks later. RESULTS: In the monitoring group, high platelet reactivity in patients taking clopidogrel (34.5% of patients) or aspirin (7.6%) led to the administration of an additional bolus of clopidogrel, prasugrel, or aspirin along with glycoprotein IIb/IIIa inhibitors during the procedure. The primary end point occurred in 34.6% of the patients in the monitoring group, as compared with 31.1% of those in the conventional-treatment group (hazard ratio, 1.13; 95% confidence interval [CI], 0.98 to 1.29; P=0.10). The main secondary end point, stent thrombosis or any urgent revascularization, occurred in 4.9% of the patients in the monitoring group and 4.6% of those in the conventional-treatment group (hazard ratio, 1.06; 95% CI, 0.74 to 1.52; P=0.77). The rate of major bleeding events did not differ significantly between groups. CONCLUSIONS: This study showed no significant improvements in clinical outcomes with platelet-function monitoring and treatment adjustment for coronary stenting, as compared with standard antiplatelet therapy without monitoring. (Funded by Allies in Cardiovascular Trials Initiatives and Organized Networks and others; ARCTIC ClinicalTrials.gov number, NCT00827411.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1209979

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 26 references

Cited by

Sorted by citations

Items 701–800 of 883

Related

See all

Metadata

Authors
Collet, J.-P., Cuisset, T., Rangé, G., Cayla, G., Elhadad, S., Pouillot, C., Henry, P., Motreff, P., Carrié, D., Boueri, Z., Belle, L., Van Belle, E., Rousseau, H., Aubry, P., Monségu, J., Sabouret, P., O'Connor, S. A., Abtan, J., Kerneis, M., Saint-Etienne, C., Barthélémy, O., Beygui, F., Silvain, J., Vicaut, E., & Montalescot, G.
Affiliations
  • Pitié-Salpêtrière Hospital (FR)
  • Hôpital de la Timone (FR)
  • Les Hôpitaux de Chartres (FR)
  • Centre Hospitalier Universitaire de Nîmes (FR)
  • Hôpital Lariboisière (FR)
  • Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
  • Hôpital Rangueil (FR)
  • Hôpital Bichat-Claude-Bernard (FR)
  • HIA du Val-de-Grâce à Paris (FR)
ORCID
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
2012-11-29
Volume
367
Issue
22
Pages
2100-2109
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejmoa1209979
OpenAlex
W2145323902
Cited by
887
References
26
Citations by year
2026: 15 · 2025: 20 · 2024: 22 · 2023: 31 · 2022: 31 · 2021: 47 · 2020: 44 · 2019: 52 · 2018: 72 · 2017: 77 · 2016: 80 · 2015: 123 · 2014: 122 · 2013: 141 · 2012: 8
FWCI
81.10
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords
antiplatelet therapy, coronary stenting, platelet function monitoring, VerifyNow P2Y12 assay, clopidogrel, prasugrel, aspirin, stent thrombosis, bleeding events, glycoprotein IIb/IIIa inhibitors, individualized dosing, major adverse cardiovascular events
MeSH terms
Prasugrel Hydrochloride, Clopidogrel, Aged, Aspirin, Coronary Disease, Coronary Thrombosis, Female, Humans, Male, Middle Aged, Myocardial Infarction, Piperazines, Platelet Aggregation Inhibitors, Pyridines, Thiophenes, Ticlopidine, Stents, Drug Monitoring, Point-of-Care Systems, Retreatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review